Renal Cell Carcinoma Features Archive
Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.
Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.
Researchers found that doubling in KIM-1 plasma concentrations was associated with an increased risk of developing RCC and poorer survival.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
A meta-analysis compared outcomes between the use of partial nephrectomy using a robotic surgical approach and open or laparoscopic partial nephrectomy.
Metabolites from the Krebs cycle were found to suppress the DNA-repair pathway required for the preservation of genomic integrity.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
Any new study of pazopanib or sunitinib must be placed in perspective of the changing treatment landscape and the market entrance of new immunotherapies.
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
The heterogeneity of kidney cancer makes each of the tumors unique and treatment decisions based on tumor characteristics especially challenging.
New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
An example of where biomarkers may help to select the best medication for a patient and also assist in drug development is the tyrosine kinase inhibitor (TKI) dovitinib for renal cell carcinoma (RCC).
Recent research indicates that there were no significant differences in the genomic landscape of clear cell RCC primary tumors and metastases, or between the different sites of metastases.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
Immunotherapy may supplant sunitinib in RCC, except for in patients who cannot tolerate checkpoint inhibition.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.
Phase 1 trials should be considered therapeutic options for some patients.
The risk should not discourage patients with cancer from taking these potentially life-extending therapies.
Several phase 3 clinical trials are likely to identify new frontline standards of care.
VEGF and PD-1 pathway inhibitors show promising improvements compared with single-agent VEGF pathway inhibitors.
While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.
Cancer Therapy Advisor asked Dr Gyawali, who coauthored a viewpoint just published in JAMA Oncology, to discuss the FDA's approval of sunitinib, and whether it is an example of what he calls "regulatory capture" in medicine.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
Close to 60% of all patients with VHL will develop RCC or renal cysts.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
A shift toward multidisciplinary care is inevitable for the treatment of locally advanced and metastatic RCC.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.
Access to treatment should be considered as important as the research leading to clinical improvements.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.
Though uncommon, complete responses are seen among patients with metastatic disease, but CRs seem to occur more often with immune checkpoint inhibitors.
The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.
A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.
A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.
Cigarettes may favor VHL-intact RCC, but it is unclear whether cigarette smoking selects for more aggressive histology of RCC in a similar way to, for example, the TP53 mutation in lung cancer.
Overexpressed CKAP4 was significantly associated with tumor, nodal, and metastasis stages, as well as Fuhrman grades.
In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.
From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.
Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.
About one-third of patients will experience disease recurrence after undergoing nephrectomy, and clinical trials exploring the use of adjuvant therapy in these patients produce conflicting results.
While renal cell carcinoma treatment continue to improve, it's unclear whether pazopanib should be used in the adjuvant setting.
In part 1 of a 2-part series, Bryant Furlow discusses advances in the understanding of inherited cancer syndromes and screening techniques for early tumor detection in high-risk patients.
Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.
Hereditary kidney cancer syndromes are often diagnosed by astute clinicians who recognize that there is more to a patient's diagnosis then just the random event of getting cancer.
As more experience with sirolimus has been gained, it began to be used "off-label" to prevent rejection in multiple transplant recipients and is now being studied in the treatment of GVHD.
There are estimated to be 13 distinct hereditary renal cell carcinoma (RCC) syndromes, each of which is associated with specific germline mutations, including von Hippel-Lindau disease (VHL).
While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.
Axitinib is an efficacious drug among patients with metastatic RCC, though selecting the appropriate patients for treatment and the correct dose can be difficult.
With researchers around the world directing their attention at the role and potential of miRNAs in RCC diagnosis and therapy, our understanding of the molecules is accelerating.
The race against malware is much the same as a war between an infectious agent and a host: it's a battle between hackers and security experts — and it's not at all clear who is winning.
Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.
The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.
The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.
Though imperiled by efforts to repeal the Affordable Care Act, the federal Open Payments transparency program is helping to expose industry payments to physicians.
In this question-and-answer session, Cancer Therapy Advisor asked Dr Iacovelli about his team's recent review regarding the future of personalizing immunotherapy for RCC.
Many cancers in humans are weakly immunogenic — if immunogenic at all — and overcoming this inherent property of cancer cells will be critical for the future success of cancer immunology.
Treating physicians should watch for any suspicious signs of cancer after DM is diagnosed.
Ulka Vaishampayan, MD, and Neeraj Agarwal, MD, spoke with Cancer Therapy Advisor about treatment recommendations for patients newly diagnosed with metastatic RCC.
If value is hard to define because it is perceived differently by different people, how can oncologists and policymakers accurately gauge cost-effectiveness?
Ongoing studies are expected to provide information about how to sequence cabozantinib in clinical practice.
Clinicians are advocating that sexual dysfunction after cancer, which affects a large proportion of survivors, be addressed as a serious quality of life issue.
In this question-and-answer session, Cancer Therapy Advisor asked Dr Roberts about direct-to-consumer genomic testing for cancer risk.
Cancer Therapy Advisor interviewed Dr Shah regarding 2 recent case studies about pediatric patients with RCC who responded to cabozantinib.
Researchers developed a novel Bayesian adaptive randomization method that maximizes efficiency by focusing the algorithm to reduce uncertainty within patient-treatment baskets.
According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.
According to the AACI, proposed budget cuts by the White House would likely mean a cut of close to $1 billion for the National Cancer Institute.
As treatment options increase, patient-reported outcomes and cost-effective analyses will play a key role in determining how drugs are sequenced in clinical practice.
Dr Clifford Pukel, a board certified medical oncologist and CEO of the Cancer Vaccine Cancer Immunotherapy (CVCI) foundation, discusses some important moments in the history of immunotherapy.
Oncologists, drug developers, and evolutionary theorists could collaborate to design treatments and treatment combinations that are more likely to succeed given the laws of natural selection.
Clinical trial investigators who receive drug industry funding are about 3.5 times as likely to find positive results as trials led by scientists who did not receive industry payments.
Researchers recently created a tool, Treeomics, to reconstruct the evolutionary pathway of metastases and to chart subclones to their anatomical locations.
At a general session at the 2017 ASCO GU Symposium, the latest advances in managing SRMs will be discussed.
Experts disagree about whether success in clinical trials translates to success in real world treatment settings.
New and old biomarkers should be included in clinical trials to help build a database from which oncologists can draw sound clinical recommendations.
Critics worry that changes to the FDA's drug approval process could lead to increased off-label prescribing and the marketing of questionable therapies.
According to the National Cancer Institute, there are not enough available data to establish whether taking vitamin D can prevent cancer.
Basket trials offer a cost-effective option to evaluate targeted agents in multiple malignancies, but it is important to be aware of their limitations.
A study of self-reported health status shows the need for physicians to consider the overall well-being of pediatric cancer survivors, for life.
Statin use in patients with kidney cancer improved cancer-specific survival and overall survival.
ROPETAR failed to demonstrate any clinical benefit in alternating treatment with pazopanib and everolimus.
CTA spoke with Judith A. Paice, PhD, RN, to better understand how clinicians are reacting to these legalizations and how she responds to patients asking about cannabis use.
Watson, hoped to be a major source for clinicians, is limited by an inability to interpret clinical trials.
Drugmaker funding for patient advocacy groups might be an important but neglected factor in rising drug prices.
More research and funding are needed to bring the benefits of precision medicine to pediatric patients.
Although there was hope that biomarkers may aid in treatment selection, research efforts to date have not yielded a viable option.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Moving Targets: Off-Label Prescribing of Targeted Therapies
- New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma
- 2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML
- Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer
- Immunotherapy Combo in Head and Neck Cancer Shows Activity in Phase 2 Trial
- Nutraceuticals/Supplements and Cancer Prevention: All Hype?
- Plastics and Cancer
- Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition
- Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Activation-Induced Cytidine Deaminase Transcripts Linked To More Aggressive CLL
- Next-Generation Sequencing Helped Identify Pathways for Transformation of WM to DLBCL
- Conditional 10-Year Breast Cancer Recurrence Rates Decline Regardless of Subtype
- Study Finds Real-World Data on Cardiac Toxicity of Trabectedin May Be Limited
- POT1 Revealed as a Sarcoma Predisposition Gene